U.S. FDA Approves GSK's Priorix Vaccine
06 June 2022 - 4:47PM
Dow Jones News
By Jaime Llinares Taboada
GSK PLC said Monday that the U.S. Food and Drug Administration
has approved its Priorix vaccine for the prevention of measles,
mumps and rubella.
The pharmaceutical company said this approval makes Priorix
available in the U.S. for the first time. The vaccine is already
licensed in more than 100 countries, including all European
countries.
"Measles, mumps and rubella are acute and highly contagious
viral diseases responsible for considerable morbidity and mortality
throughout the world. In recent years, measles outbreaks have
occurred in the U.S. and globally, with more than 400,000 cases
confirmed in 2019," Senior Vice President Judy Stewart said.
Write to Jaime Llinares Taboada at jaime.llinares@wsj.com;
@JaimeLlinaresT
(END) Dow Jones Newswires
June 06, 2022 02:32 ET (06:32 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Gsk (LSE:GSK)
Historical Stock Chart
From Mar 2024 to Apr 2024
Gsk (LSE:GSK)
Historical Stock Chart
From Apr 2023 to Apr 2024
